Sentence examples for rationale for development of from inspiring English sources

The involvement of FGF/FGFRs in the pathology of many cancer types provides a strong rationale for development of effective agents for these targets and a large effort to develop FGFR inhibitors as anticancer treatments is underway (Brooks et al., 2012, Dieci et al., 2013).

Hence inhibiting the eIF4F checkpoint suppresses tumor growth through multiple mechanisms and provides a rationale for development of broad-acting therapeutics.

These data indicate that Plasmodium SPP is a potential therapeutic target for malaria, and provide rationale for development of selective Plasmodium SPP inhibitors, perhaps based on the LY411,575 scaffold as novel treatments for malaria.

The rationale for development of the isotope-coded NEM approach was to allow future extension to measurement in parallel of both RSNO and SS protein modifications.

This provides the basis and rationale for development of knowledge-based learning outcomes for pharmacology that can inform pharmacology teaching across degree programs with minimum standards articulated for each degree program.

Thus there is a strong rationale for development of IGF-1R targeted therapies, and IGF-1R inhibition might be expected to enhance the effect of cytotoxic chemotherapies or other molecular targeted therapies.

Thus, careful evaluation of both the mechanistic and functional consequences between RIDD activation versus XBP1/HAC1 splicing will provide a greater understanding of how ER stress affects cell physiology and also provide rationales for development of drugs and more effective treatment strategies for ER stress-related diseases.

This observation provided the rationale for the development of inhibitors of the EGFR-mediated signalling cascade as anticancer therapeutics (Ciardiello, 2000a).

A major component of the rationale for the development of ciclesonide is the minimization of local and systemic side effects often experienced with inhaled corticosteroids.

In conclusion, our data demonstrate that the presence of chemically senescent prostate cancer cells does not significantly enhance the growth of tumour xenografts, providing further rationale for the development of anticancer strategies that efficiently induce senescence in advanced cancers.

Collectively, these findings have provided strong rationale for the development of small-molecule inhibitors of MEK1/2 for chemotherapeutic intervention in cancer.